Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 09:28am CEST

(Reuters) - Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

(Reuters) - Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

The dispute between the Jordan-based firm, its partner Vectura (>> Vectura Group PLC) and the U.S FDA delays any eventual approval of the generic version of the drug.

Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

Hikma, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business.

In August it had lowered its generics revenue guidance by $50 million to about $620 million citing higher pricing pressures in the industry, having slashed it to $670 million from an initial $800 million last November.

The company, that has been hit by higher price erosion levels than the rest of the industry, has been re-negotiating its contracts with suppliers and third-party vendors to cut costs to try to boost profitability.

"We expect these market conditions to persist in 2018 and are actively pursuing new commercial opportunities and focussing on the execution of our pipeline to help offset continuing price erosion across the industry," it said in a statement.

The company, which cut its full-year guidance in May to the range of $2 billion-$2.1 billion from $2.2 billion, said in August that it expected 2017 revenue to be at the lower end of the range at $2 billion.

Hikma reiterated its 2017 revenue expectations on Thursday.

Earlier this month, Israeli-based Teva Pharmaceutical (>> Teva Pharmaceutical Industries Limited), the world's biggest generics drugmaker, said it would miss 2017 profit forecasts citing falling prices of generics in the U.S. market and weakening sales of its multiple sclerosis drug.

Hikma's lower guidance in May followed a decision by U.S. regulators not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application.

Hikma said it expected the dispute process with the FDA to be completed in the first quarter of 2018.

(Reporting by Justin George Varghese in Bengaluru and Ben Hirschler in London; editing by Jason Neely and Keith Weir)

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 1.53% 1486 Delayed Quote.10.67%
HIKMA PHARMACEUTICALS 3.79% 1782 Delayed Quote.51.41%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2.68% 8038 Delayed Quote.20.64%
VECTURA GROUP PLC 4.45% 72.8 Delayed Quote.-40.78%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
10/15AstraZeneca will keep UK investment freeze if no Brexit clarity
RE
10/15AstraZeneca will keep UK investment freeze if no Brexit clarity
RE
10/11ALBIREO PHARMA : Appoints Simon Harford as Chief Financial Officer and Treasurer
AQ
10/09GLAXOSMITHKLINE : helps immunometabolism startup Sitryx to $30M round
AQ
10/09MANAGEMENT TRACKS : As Akcea shifts to commercialization, Crooke resigns from bo..
AQ
10/08PIERRE FABRE : sources
RE
10/08GLAXOSMITHKLINE : Gene therapy developer Orchard proposes IPO
AQ
10/05BIOCENTURY - MANAGEMENT TRACKS : Grail, Nimbus
AQ
10/04GLAXOSMITHKLINE : Biopharmaceutical Firm Orchard Plans U.S. IPO
DJ
10/04Phage display founders win Nobel for chemistry
AQ
More news
News from SeekingAlpha
10/15FDA issues new guidance aimed at more efficient drug development 
10/15Healthcare 16-24% Target Net Gains Pace WallStars For October 
10/13STOCKS TO WATCH : Was That A Speed Bump? 
10/13RETIREMENT : How To Manage Risks And Prepare For The Next Downturn 
10/09Altimmune Declines Too Much 
Financials (GBP)
Sales 2018 30 371 M
EBIT 2018 8 156 M
Net income 2018 3 396 M
Debt 2018 20 488 M
Yield 2018 5,47%
P/E ratio 2018 21,05
P/E ratio 2019 16,44
EV / Sales 2018 3,07x
EV / Sales 2019 2,96x
Capitalization 72 602 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 16,4  GBP
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE10.67%95 454
JOHNSON & JOHNSON-4.19%359 141
PFIZER20.87%256 643
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%204 254
MERCK AND COMPANY23.44%185 661